1)Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 61 : 1-241, 1994
2)Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 : 784-789, 2001
3)Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 109 : 138-143, 2004
4)井上和彦,東山真,谷充理,他.国内分離株から作成された血清ヘリコバクターピロリ抗体を用いた,ペプシノゲン法併用による胃の‘健康度'評価.日がん検診断会誌 12 : 138-143, 2005
5)Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter 16 : 415-419, 2011
6)Toller IM, Neelsen KJ, Steger M, et al. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double strand breaks and a DNA damage response in its host cells. Proc Natl Acad Sci USA 108 : 14944-14949, 2011
7)井上和彦.人間ドックにおけるHelicobacter pylori検査の実態.Helicobacter Res 11 : 562-567, 2007
8)乾純和,吉川守也,安部純,他.住民検診においてHelicobacter pylori検査はどのように活用されるか?─血清H. pylori抗体価,血清ペプシノゲン値同時測定による胃がん検診(ABC検診)の試み.Helicobacter Res 11 : 554-561, 2007
9)Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China : a randomized controlled trial. JAMA 291 : 187-194, 2004
10)Take S, Mizuno M, Ishii K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 42 : 21-27, 2007
11)Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randomised controlled trial. Lancet 372 : 392-397, 2008
12)大和田進,乾純和,乾正幸,他.ABC検(健)診による胃癌リスク分類と内視鏡所見.Helicobacter Res 15 : 432-438, 2011
13)大和田進,乾純和,乾正幸.Letter to Editor内視鏡ABC分類.Helicobacter Res 15 : 583-584, 2011
14)Tytgat GN. The Sydney System : endoscopic division, Endoscopic appearances in gastritis/duodenitis. J Gastroenterol Hepatol 6 : 223-234, 1991
15)Nakagawa S, Kato M, Shimizu Y, et al. Relationship between histopathologic gastritis and mucosal microvascularity : observations with magnifying endoscopy. Gastrointest Endosc 58 : 71-75, 2003
16)乾純和,大和田進,乾正幸.わが国の胃がん対策について─その現状と将来展望.The GI Forefront 7 : 23-26, 2012
17)乾純和,大和田進,吉川守也.胃がんリスク層別化後の経鼻内視鏡検査.日本がん検診断会誌 17 : 181-190, 2010
18)乾純和,大和田進,近藤裕子,他.経鼻内視鏡による胃癌スクリーニングの現状と問題点─地域検診の立場から.胃と腸 43 : 1230-1240, 2008
19)萩原廣明,山下由起子,八木茂,他.多施設内視鏡胃がん個別検診における経鼻内視鏡の現状と精度.日本消化器がん検診学会雑誌 47 : 683-692, 2009
20)井上晴洋.食道疾患の内視鏡診断と治療.医学書院,pp 7-39,2009
21)吉澤充代,大澤博之,山本博徳,他.FICEによる早期食道癌の存在・質的診断法.胃と腸 43 : 1462-1470, 2009
22)蘇原直人,小野里康博,飯塚春尚.経鼻内視鏡での早期食道癌発見にはNBI観察が有用である.Gastroenterol Endosc 52 : 769, 2010
23)Yagi J, Adachi K, Arima N, et al. A prospective randomized comparative study on the safety and tolerability of transnasal esophagogastroduodenoscopy. Endoscopy 37 : 1226-1231, 2005
24)坂野閣紀,宮原良二,舩坂好平,他.盲点の除去に何が必要か─生検の仕方を含めて.消内視鏡 23 : 1048-1055, 2011
25)小越和栄,成澤林太郎,加藤俊幸,他.新潟市住民に対する胃がん内視鏡検診.ENDOSCOPIC FORUM digest dis 26 : 5-16, 2010